Ma Guang-Yuan, Hou Lu-Kuan, Guo Jia-Hui, Sun Jing-Chun, Nong Qiuna, Wang Yu-Fan, Hu Sheng-Wei, Zhao Wen-Jing, Tan Jin, Liu Xiao-Feng, Guo Yuan, Zhang Bo-Jing, Wang Hong-Ling, Wang Shu-Yao, Li Xiao-Qiang, Cao Wei
Shaanxi Key Laboratory of Natural Products & Chemical Biology, School of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China.
Department of Chinese Materia Medica and Natural Medicines, School of Pharmacy, Air Force Medical University, Xi'an 710032, China; Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, School of Pharmacy, Air Force Medical University, Xi'an 710032, China.
Carbohydr Polym. 2025 Apr 1;353:123290. doi: 10.1016/j.carbpol.2025.123290. Epub 2025 Jan 17.
Type 2 diabetes mellitus (T2DM) is characterized by impaired cellular or organ responsiveness to insulin, which results in ineffective glucose disposal and lacks a definitive treatment. Previous studies suggest that polysaccharides hold promise as natural agents for the prevention and treatment of T2DM. In this study, we identified two polysaccharides from Fructus Corni, PFC-CI and PFC-CII, with molecular weights of 59.0 kDa and 26.0 kDa, respectively. PFC-CI consists of T-α-Galp-(1→6)-α-Galp-(1→6)-α-Galp-(1→[4)-GalpA-(1→4)-GalpA-OMe-(1→4)-α-GalpA-3-OAc-(1→]→[2)-Rhap-(1→4)-α-GalpA-(1→], with side chains composed of α-Araf-(1→, →3)-α-Araf-(1→, →3,5)-α-Araf-(1→, →5)-α-Araf-(1→. PFC-CII is a linear α-1,6-glucan. Among them, PFC-CI showed superior effects on promoting glucose consumption and uptake in insulin-resistant (IR) HepG2 cells. In vivo, PFC-CI significantly alleviate IR in high-fat diet and streptozotocin-induced diabetic rats, indicating its potential as a therapeutic agent for T2DM. Mechanistically, PFC-CI modulates the glucose transporter 2 (Glut2)/glucokinase signaling pathway, thereby exerting anti-T2DM effects. This research indicates that Fructus Corni contains a potential therapeutic polysaccharide as a specific regulator of Glut2 for treating T2DM.
2型糖尿病（T2DM）的特征是细胞或器官对胰岛素的反应受损，这导致葡萄糖处理无效且缺乏明确的治疗方法。先前的研究表明，多糖有望作为预防和治疗T2DM的天然药物。在本研究中，我们从山茱萸中鉴定出两种多糖，即PFC-CI和PFC-CII，分子量分别为59.0 kDa和26.0 kDa。PFC-CI由T-α-Galp-(1→6)-α-Galp-(1→6)-α-Galp-(1→[4)-GalpA-(1→4)-GalpA-OMe-(1→4)-α-GalpA-3-OAc-(1→]→[2)-Rhap-(1→4)-α-GalpA-(1→]组成，其侧链由α-Araf-(1→, →3)-α-Araf-(1→, →3,5)-α-Araf-(1→, →5)-α-Araf-(1→组成。PFC-CII是一种线性α-1,6-葡聚糖。其中，PFC-CI在促进胰岛素抵抗（IR）的HepG2细胞中的葡萄糖消耗和摄取方面表现出优异的效果。在体内，PFC-CI显著减轻高脂饮食和链脲佐菌素诱导的糖尿病大鼠的IR，表明其作为T2DM治疗药物的潜力。从机制上讲，PFC-CI调节葡萄糖转运蛋白2（Glut2）/葡萄糖激酶信号通路，从而发挥抗T2DM作用。本研究表明，山茱萸含有一种潜在的治疗性多糖，作为治疗T2DM的Glut2特异性调节剂。
